menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    MannKind`s Ph 1 Trial of Nintedanib DPI for Pulmonary Fibrosis

    GLOBENEWSWIRE

    Boehringer`s Lung Fibrosis Trial Meets Primary Endpoint

    FIERCE BIOTECH

    MannKind to Proceed with Ph1 Nintedanib DPI (MNKD-201) in PF

    GLOBENEWSWIRE

    U.S. FDA accepts supplemental New Drug Application for OFEV for children

    PR NEWSWIRE

    Lotus` Generic Nintedanib Esylate Receives Approval in the U.S.

    FDA

    Lotus` Generic Nintedanib Receives Approval in the U.S.

    FDA

    New data from Boehringer support the potential use of nintedanib

    BUSINESSWIRE

    NICE approves Ofev for PF-ILD

    PHARMATIMES

    Blade shows +ve Data from Drug-Drug Interaction Study of Cudetaxesta in IPF

    BUSINESSWIRE

    SMC approves nintedanib for patients with chronic lung disease

    PHARMAFILE

    Study analysis available during ATS 2021 supports long-term treatment with Ofev®

    PRNEWSWIRE

    OFEV® (nintedanib) receives positive recommendation from CADTH and INESSS

    NEWSWIRE

    Boehringer and Icahn School begin enrolment in Covid-19 trial

    CLINICALTRIALSARENA

    CohBar Antifibrotic Peptide in Combination Nintedanib Shows Enhanced Effects

    PRESS RELEASE

    Cipla launches Nintib Idiopathic Pulmonary Fibrosis, in continuation

    PRESS RELEASE

    Boehringer starts enrolment for paediatric trial of nintedanib

    CLINICALTRIALSARENA

    Phase III InPedILD™ trial enrolls first patient to evaluate nintedanib pediatric

    PRNEWSWIRE

    Accord Healthcare`s Generic Nintedanib Receives Approval in US

    FDA

    New Analyses of Ofev® data in patients with chronic fibrosing ILDs during ATSC

    PRNEWSWIRE

    Boehringer Ingelheim gets European approval for additional for nintedanib

    PHARMABIZ

    European Commission approves third nintedanib indication in pulmonary fibrosis1

    BUSINESSLWIRE

    European Commission approves third nintedanib indication in pulmonary fibrosis1

    BUSINESSLWIRE

    BI receives positive CHMP opinion for a third nintedanib indication

    BUSINESSWIRE

    OFEV® (nintedanib) now available in Canada for adults living with (PF-ILD)(1)

    NEWSWIRE

    AI VIVO seeks pharma, biotech collaboration partners to advance drug candidates

    MEDICAL

    CHMP Recommends One New Drug, Begins Review of Indian CRO

    RAPS

    Boehringer’s nintedanib secures breakthrough status in US for ILDs

    PHARMACEUTICAL TECHNOLOGY

    FDA Grants Ofev® Breakthrough Therapy Designation

    PR NEWSWIRE

    Boehringer Ingelheim`s Ofev wins FDA approval for use in scleroderma patients

    ENDPOINTSNEWS

    FDA approves Boehringer`s lung disease drug

    REUTERS

    Ofev set for new US approval, in scleroderma

    THE PHARMALETTER

    Boehringer expands IPF pipeline with addition of BBT-877

    PHARMATIMES

    Nintedanib hits targets in rare lung disease trial

    PHARMA TIMES

    Phase III study showed nintedanib slows the loss of pulmonary function

    BUSUNESSWIRE

    Boehringer eyes rare disease use for respiratory blockbuster

    PMLIVE

    Genentech Plans Legal Battle to Protect Esbriet from Generic Competition

    Tium Bio Licenses out Lung Disease Drug Candidate for US$74 Mil

    KOREA BUSINESS

    List of Paragraph IV Patent Certifications as of Dec 18, 2018

    FDA

    FDA Confirms Paragraph IV Patent Challenge of Nintedanib 100 mg and 150 mg Capsules (Ofev 205832)

    FDA

    Vargatef® plus docetaxel could be option after failure of immunotherapy in LC

    BUSINESSWIRE

    Ofev® (nintedanib) slows progression of IPF beyond 4yrs with consistent safety

    PR NEWSWIRE

    Boehringer sales rise as Jardiance and Ofev thrive

    PHARMA TIMES

    Efficacy and safety of Ofev® reinforced in new presentations at ATS 2018

    PR NEWSWIRE

    FDA grants Fast Track designation to nintedanib for the of systemic sclerosis

    BIOSPACE

    PIM status for Boehringer’s mesothelioma drug

    PHARMA TIMES

    FibroGen Announces Positive Topline Results from Ph2 Study of Pamrevlumab

    GLOBENEWSWIRE

    IPF patients treated with Ofev v. placebo were twice have improved lung function

    PR NEWSWIRE

    UK competition watchdog accuses Merck of obstructing biosimilars

    REUTERS

    Nintedanib granted orphan drug designation for treatment of mesothelioma

    PR NEWSWIRE

    Bristol-Myers pens $100M NASH, fibrosis drug deal with Japan’s Nitto

    FIERCE BIOTECH

    BI unveils new data backing IPF drug Ofev

    PHARMATIMES

    Boehringer`s Vargatef Comes up One Endpoint Short in Colorectal Cancer Effort

    FIERCE PHARMA

    Phase III nintedanib announced at ESMO

    PR NEWSWIRE

    US/EU orphan status for BI’s Ofev in systemic sclerosis

    PHARMATIMES

    New presentations at ATS 2016 reinforce OFEV efficacy, safety and tolerability

    CPHI-ONLINE

    Boehringer, AbbVie Said to Be in Cancer-Partnership Talks

    BLOOMBERG

    BI launches unique drug for rare disease and revolutionizes panorama treatment

    PR NEWSWIRE

    New analysis OFEV slows disease progression in IPF, reduces risk exacerbations

    PR NEWSWIRE

    New PhIII Study of Nintedanib in People with Systemic Sclerosis,Lung Fibrosis

    PR NEWS WIRE

    New Analyses Further Add to the Efficacy and Safety Profile of OFEV in IPF

    FINANCIAL EXPRESS

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.